Who
Alan Fuhrman
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Tyra Biosciences; Director, SpringWorks Therapeutics; Director, Esperion Therapeutics; Director and Officer, Checkmate Pharmaceuticals; Director, Loxo Oncology; Chief Financial Officer, Synlogic; Chief Financial Officer, Ambit Biosciences; Senior Vice President & CFO, Achieve Life Sciences.
In numbers
- Trades disclosed
- 75
- Buys
- 1
- Sells
- 1
- Bought
- $152K
- Sold
- $467K
- Companies
- 8
- Companies where not an officer
- 3
- First trade
- 16 Dec 2005
- Last trade
- 15 Sep 2026
- Last filed
- 17 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Sep 2026filed 17 Sep 2026 | TYRA Tyra BiosciencesBiotechnology | SEC FORM 4 Code A | $8,682951 at $9.13 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TYRA Tyra BiosciencesBiotechnology | SEC FORM 4 Code A | $8,683951 at $9.13 | filing |
| 5 May 2026filed 7 May 2026 | TYRA Tyra BiosciencesBiotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 5 May 2026filed 7 May 2026 | TYRA Tyra Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —67,000 at $0.00 | filing |
| 5 May 2026filed 7 May 2026 | TYRA Tyra Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —67,000 at $0.00 | filing |
| 5 May 2026filed 7 May 2026 | TYRA Tyra BiosciencesBiotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 13 Mar 2026filed 17 Mar 2026 | TYRA Tyra BiosciencesBiotechnology | SEC FORM 4 Code A | $13K1,376 at $9.13 | filing |
| 13 Mar 2026filed 17 Mar 2026 | TYRA Tyra BiosciencesBiotechnology | SEC FORM 4 Code A | $13K1,376 at $9.13 | filing |
| 15 Sep 2025filed 17 Sep 2025 | TYRA Tyra BiosciencesBiotechnology | SEC FORM 4 Code A | $6,400701 at $9.13 | filing |
| 7 Aug 2025filed 7 Aug 2025 | TYRA Tyra Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —170,000 at $0.00 | filing |
| 1 Jul 2025filed 2 Jul 2025 | SpringWorks Therapeuticsoption or derivative | SEC FORM 4 Code D | —29,983 | filing |
| 1 Jul 2025filed 2 Jul 2025 | SpringWorks Therapeuticsoption or derivative | SEC FORM 4 Code D | —7,464 | filing |
| 1 Jul 2025filed 2 Jul 2025 | SpringWorks Therapeuticsoption or derivative | SEC FORM 4 Code D | —15,318 | filing |
| 1 Jul 2025filed 2 Jul 2025 | SpringWorks Therapeuticsoption or derivative | SEC FORM 4 Code D | —13,774 | filing |
| 1 Jul 2025filed 2 Jul 2025 | SpringWorks Therapeuticsoption or derivative | SEC FORM 4 Code D | —12,216 | filing |
| 1 Jul 2025filed 2 Jul 2025 | SpringWorks Therapeutics | SEC FORM 4 Code D | —24,727 | filing |
| 14 May 2025filed 15 May 2025 | SpringWorks Therapeutics | SEC FORM 4 Code A | —10,060 at $0.00 | filing |
| 14 Mar 2025filed 18 Mar 2025 | TYRA Tyra BiosciencesBiotechnology | SEC FORM 4 Code A | $12K1,238 at $9.78 | filing |
| 30 Oct 2024filed 1 Nov 2024 | TYRA Tyra BiosciencesBiotechnology | SEC FORM 4 Bought | $152K9,500 at $16.00 | filing |
| 13 Sep 2024filed 17 Sep 2024 | TYRA Tyra BiosciencesBiotechnology | SEC FORM 4 Code A | $12K954 at $12.48 | filing |
News
No headline names them, or the companies they trade most, lately.